ATXS
Astria Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Astria Therapeutics (ATXS) Stock: Buy, Sell, or Hold?
$12.58
+0.08 (+0.64%)
▲
5d:
+0.32%
30d:
-1.95%
90d:
+3.45%
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (70%)
Quality Score
54/100
Position
FAIR
Forward P/E & Valuation
-5.3x
Next 12M consensus est.
Wall Street Target
$24.60
+95.5% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$12.24 / $13.27
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: ATXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
Get Alerted When ATXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: ATXS is currently trading at $12.58, which is considered fair based on recent price action.
Technical Outlook: Technically, ATXS is in a strong uptrend. The price is currently testing key support at $12.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $24.60 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ATXS is in a strong uptrend. The price is currently testing key support at $12.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $24.60 (+95.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
54/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
69.5%
Trading Range & Key Levels
Support Level
$12.24
Resistance Level
$13.27
Current Trend
Strong Uptrend
Technical data as of
Jan 22, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Trading 95.5% below Wall St target ($24.60)
- NEUTRAL: Bottoming setup forming (40/100) — watch for confirmation
Fundamental Context
Forward P/E (Next Year Est.)
-5.34
Wall Street Target
$24.60
(+95.5%)
Share ATXS Analysis
Share this live ATXS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 11, 2026 9:50 AM ET
Data refreshes hourly during market hours. Next update: 10:50 AM
Data refreshes hourly during market hours. Next update: 10:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeOne Medicines AG |
STRONG BUY
27 analysts |
$438 | 40 SELL |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$302 | 49 HOLD |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
15 analysts |
$22 | 72 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 66 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive ATXS Research Pages
